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TECHNOLOGY AND GUIDELINES
Secondary prevention for patients following a myocardial
infarction: summary of NICE guidance
J S Skinner, A Cooper, G S Feder, on behalf of the Guideline Development Group
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Mortality from coronary heart disease has been falling in the UK
since the 1970s, but remains higher than in most other Western
countries. Most patients receive some treatment for secondary
prevention after myocardial infarction, but not all patients are
offered the most effective secondary prevention package. The
recently published NICE guideline for secondary prevention in
patients after myocardial infarction, summarised in this article,
makes clear recommendations for management of patients after
myocardial infarction, based on best available evidence. The
guidelines update the 2001 NICE guideline, and have expanded
and emphasised the recommendations for physical activity,
dietary and other lifestyle changes, and cardiac rehabilitation,
and updated the recommendations for drug therapy.
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A
lthough mortality from coronary heart dis-
ease in the UK has fallen since the 1970s, it
remains higher than in most other Western
countries, with over 103 000 deaths per year. Since
the publication of the National Service Framework for
coronary heart disease in 2000,1 many patients are
prescribed aspirin, beta blockers, ACE inhibitors
and statins following myocardial infarction.
However, not everyone is offered the most effective
package for secondary prevention. Patients are not
always prescribed all four of these drugs or other
effective drugs, nor do they always receive advice
about lifestyle changes and access to cardiac
rehabilitation. This guideline clearly sets out the
recommendations for effective secondary preven-
tion in patients after myocardial infarction. It
updates the 2001 NICE guideline Prophylaxis for
patients who have experienced a myocardial infarction.2
The recommendations for physical activity, dietary
changes and rehabilitation have been expanded
and emphasised, and the recommendations for
drug therapy updated. The guideline makes
recommendations for patients after an acute
myocardial infarction and also for those who have
had a proven myocardial infarction at any time in
the past.
The detailed consideration of the evidence for
this guideline is available in the full version (see
http://www.nice.org.uk/CG048).
RECOMMENDATIONS
NICE recommendations are based on systematic
reviews of best available evidence. For guidance on
secondary prevention for patients after a myocar-
dial infarction, in cases where minimal evidence
was available, the guideline development group
created the recommendations on the basis of their
own opinions and those of leading specialists;
such recommendations are indicated with an
asterisk (*).
After a myocardial infarction, confirmation of
the diagnosis of acute myocardial infarction and
results of investigations, future management plans
and advice on secondary prevention should be part
of every discharge summary*.
Lifestyle
Lifestyle advice should be consistent, take account
of patients’ current habits and any changes
tailored to the individual.
Patients should be advised to:
N Take regular physical activity sufficient to
increase exercise capacity (reduces total mor-
tality), and building up physical activity to
20–30 min/day to the point of slight breath-
lessness.
N Stop smoking. Support and advice, and phar-
macotherapy should be offered to those who
have expressed a desire to quit.3 4
N Eat a Mediterranean-style diet—more bread,
fruit, vegetables and fish; less meat; and replace
butter and cheese with products based on
vegetable and plant oils (reduces total mortality
and the risk of myocardial infarction).
N Consume at least 7 g of omega-3 fatty acids per
week from 2–4 portions of oily fish per week. If
within 3 months of a myocardial infarction and
they are not achieving this, consider providing
at least 1 g daily of omega-3-acid ethyl esters
treatment licensed for secondary prevention
after myocardial infarction for up to 4 years.
Initiation of omega-3-acid ethyl esters supple-
ment treatment is not routinely recommended
in patients that have had a myocardial infarc-
tion more than 3 months earlier (no evidence of
benefit).
N Achieve and maintain a healthy weight.
Patients who are overweight or obese should
be offered appropriate advice and support.5
N Restrict their alcohol intake to within recom-
mended safe limits of 14 units per week for
women and 21 units per week for men, and
avoid binge drinking*.
Patients should be advised against taking:
N Supplements containing beta-carotene (may
increase risk of cardiovascular death).
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N Antioxidant supplements (no evidence of benefit).
N Folic acid supplements (no evidence of benefit).
Cardiac rehabilitation
Cardiac rehabilitation should be actively promoted by all
healthcare professionals, including senior medical staff,
involved in providing care for patients after a myocardial
infarction*.
Cardiac rehabilitiation:
N With an exercise component (reduces mortality) should be
offered to all patients, and made accessible regardless of the
patient’s age, gender, ethnicity, socioeconomic status or
comorbidities.
N Should include the following components: exercise (reduces
mortality), health education, and stress management
(reduces anxiety, depression and the risk of non-fatal
myocardial infarction); however complex psychological
interventions such as cognitive behavioural therapy should
not be routinely offered.
N Should involve partners or carers, if the patient wishes*.
N May be a validated home-based programme, such as the
Edinburgh Heart Manual,6 with follow up by a trained
facilitator.
N Should include advice about return to activities of daily
living and return to work; any advice should take account of
the physical and psychological status of the patient, the
nature of the activity or work proposed and the work
environment*.
N Should include reassurance that after recovery from a
myocardial infarction sexual activity does not pose a greater
risk of triggering a subsequent episode than in a person who
has never had a myocardial infarction.
N Should take into account the patient’s wider health and
social needs, which may involve identifying and addressing
economic, welfare rights, housing or social support issues.
This may be a particular issue for patients in more deprived
situations, and rehabilitation services should assess the
likely scale of these needs when planning how their services
meet the needs of the local population*.
Drug treatment after acute myocardial infarction
N All patients should be offered combined treatment with the
following:
– ACE (angiotensin-converting enzyme) inhibitor (reduces
total mortality, the risk of myocardial infarction and, in
selected patients, the risk of developing heart failure)
– Aspirin (reduces cardiovascular mortality and morbidity)
– Beta blocker (reduces mortality and cardiovascular
morbidity)
– Statin (reduces mortality and major cardiovascular
morbidity).
N Clopidogrel in combination with aspirin is recommended for
12 months in patients after a non-ST elevation myocardial
infarction7 (reduces cardiovascular mortality and the risk of
myocardial infarction and stroke), and for at least 4 weeks in
patients after a ST elevation myocardial infarction (reduces
total mortality and the risk of myocardial infarction and
stroke). Thereafter, standard treatment, including low dose
aspirin should be continued, unless there are other indica-
tions to continue dual antiplatelet agents.
N Patients with heart failure and left ventricular systolic
dysfunction should be offered a licensed aldosterone
antagonist within 3–14 days of the acute myocardial
infarction, preferably after ACE inhibitor therapy (reduces
total mortality and the risk of hospitalisation for cardiovas-
cular events including heart failure).
N Moderate intensity warfarin (INR 2–3) can be considered in
patients intolerant of both aspirin and clopidogrel (reduces
the risk of myocardial infarction). In patients after an acute
myocardial infarction who are intolerant to clopidogrel and
have a low risk of bleeding, treatment with aspirin and
moderate intensity warfarin combined should be considered.
N In patients already treated with warfarin for another
indication, warfarin should be continued. In those treated
with moderate intensity warfarin and who have a low risk of
bleeding, the addition of aspirin should be considered.
Cardiological assessment
N Patients should be offered a cardiological assessment, taking
into account comorbidity, to identify patients who will
benefit from coronary revascularisation for secondary pre-
vention (reduces the risk of myocardial infarction and
improves survival in appropriately selected patients), or
from other cardiological interventions.8
OVERCOMING BARRIERS
N Ensure timely communication between hospitals and pri-
mary care to ensure that appropriate therapy is continued,
monitored and uptitrated following discharge.
N Adapt current post-myocardial infarction pathways to
ensure that all patients are offered access to a cardiac
rehabilitation programme and have appropriate cardiological
assessment.
N Incorporate advice about lifestyle into standard models of
care.
N GPs should review their disease registers and ensure that all
eligible patients with a proven myocardial infarction in the
past are being appropriately managed.
UNANSWERED RESEARCH QUESTIONS
N How long should patients with ST elevation myocardial
infarction treated with thrombolysis take aspirin plus
clopidogrel, compared with aspirin alone?
N How effective is long-term continuation of drugs for
secondary prevention after a myocardial infarction? For
example, do all patients with normal left ventricular
function benefit from long-term beta blockers and ACE
inhibitors?
N How effective is spironolactone compared with eplerenone in
patients with heart failure and left ventricular dysfunction
early after myocardial infarction?
N What strategies are effective in improving uptake and
adherence to comprehensive cardiac rehabilitation pro-
grammes, particularly in groups under-represented in those
programmes?
N What is the added value of the non-exercise components of
comprehensive cardiac rehabilitation programmes?
N How effective are omega-3-acid ethyl esters in all patients
after myocardial infarction?
N What measures encourage the maintenance of regular
exercise and a Mediterranean-style diet beyond the period
of comprehensive cardiac rehabilitation?
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T
he recently published NICE guideline MI: secondary preven-
tion in primary and secondary care for patients following a
myocardial infarction1 updates the previous guideline pub-
lished in 20012 and the relevant sections of the National Service
Framework for coronary heart disease.3 The guideline is important
to clinicians in both primary and secondary care, and to those
who plan services. There have been significant improvements in
recent years and the majority of eligible patients leaving
hospital after an acute myocardial infarction are now treated
with aspirin and statins. However, other important interven-
tions such as advice about lifestyle and cardiac rehabilitation
are less consistently provided and there is inconsistent practice
with regards to some drug therapies. This guideline makes
recommendations for lifestyle and cardiac rehabilitation in far
greater detail than in the previous one, as well as updating and
expanding the recommendations for drug treatment.
Patients who have just had an acute myocardial infarction are
readily identifiable, and this guideline addresses secondary
prevention after the very early acute phase. It also makes
recommendations for the management of patients with a proven
myocardial infarction in the past. These patients will generally no
longer be under hospital follow-up and it will be the responsi-
bility of primary care to review patients on their disease registers
to ensure that management has been optimised.
DRUG TREATMENT
The recommendations that aspirin, beta blockers, statin and ACE
inhibitors be considered in all patients after acute myocardial
infarction are maintained in this guideline and further supple-
mented to include appropriate treatment with a combination of
aspirin and clopidogrel, and early treatment with an aldosterone
antagonist in patients with heart failure. Other drugs such as
vitamin K antagonists are also now included.
Recommendations for treatment with the combination of
aspirin and clopidogrel in non-ST elevation myocardial infarction
restate those of the NICE technology appraisal number 80,
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary
syndrome,4 to continue treatment for a year. After an ST elevation
myocardial infarction patients who have been thrombolysed and
treated with clopidogrel and aspirin on initial presentation should
continue with both agents for at least four weeks. However,
evidence is lacking as to the optimal duration of treatment with
both agents in patients after an ST elevation myocardial infarction
and, in practice, clinicians in secondary care should make explicit
recommendations for the duration of dual antiplatelet therapy as
part of the patient management plan. Further research to examine
the optimal duration of dual antiplatelet therapy in this group is
recommended in the guideline.
Treatment with both aspirin and clopidogrel is not routinely
recommended for longer than a year. Treatment plans can be
made in secondary care, but most patients who have had a
myocardial infarction will no longer be under hospital follow-up
one year later. Primary care will need to make sure that patients
have an individual review before stopping clopidogrel to ensure
that other indications to continue both agents have not developed.
Patients with heart failure after myocardial infarction are at
high risk for further events and early treatment (within 3–
14 days) with an aldosterone antagonist licensed for this
indication is recommended in patients who have had symptoms
and signs of heart failure and a left ventricular ejection fraction
of 40% or less, preferably after an ACE inhibitor. This means
that all patients with heart failure after acute myocardial
infarction will require an early assessment of left ventricular
function, generally before discharge, so that appropriate
treatment can be initiated in those fulfilling the criteria. This
may prove a challenge for some units and services should
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